

Table 1. POM121 expression in ALL and AML patients and its relationship with certain clinical and laboratory findings.

	<b>ALL POM121 expression (mean±SD) (min-max)</b>	<b>n</b>	<b>p</b>	<b>AML POM121 expression (mean±SD) (min-max)</b>	<b>n</b>	<b>p</b>
Boys	4.18±3.35 0.24-13.45	39	0.117	4.09±4.56 0.50-16.79	13	0.162
Girls	2.92±1.54 1.035-7.67	20		8.57±9.59 0.07-27.28	8	
Anemia (-)	2.53±1.31 1.02-3.41	3	*		0	*
Anemia (+)	3.81±2.97 0.24-13.45	56		5.80±7.05 0.07-27.28	21	
Neutropenia (-)	4.28±3.15 0.24-13.45	44	0.016	5.90±7.32 0.07-27.28	15	0.921
Neutropenia (+)	2.20±1.09 1.00-5.10	15		5.55±6.95 0.50-18.64	6	
Thrombocytopenia (-)	3.10±2.53 0.24-10.70	17	0.278	5.35±4.05 0.07-8.63	5	*
Thrombocytopenia (+)	4.01±3.05 1.02-13.45	42		5.94±7.86 0.05-27.28	16	
Splenomegaly (-)	3.59±3.12 0.24-13.00	30	0.678	3.83±5.23 0.07-18.64	12	0.144
Splenomegaly (+)	3.91±.74 1.02-13.45	29		8.42±8.54 1.26-27.28	9	
Hepatomegaly (-)	3.30±2.73 0.24-13.00	28	0.264	4.13±5.41 0.07-18.64	11	0.144
Hepatomegaly (+)	4.16±3.06 0.63-13.45	31		7.64±8.40 1.26-27.28	10	
Lymphadenopathy (-)	3.47±2.90 0.24-13.45	35	0.379	7.46±8.43 0.50-27.28	13	0.175
Lymphadenopathy (+)	4.16±2.94 0.63-13.00	24		3.10-2.57 0.07-8.11	8	
Relapse (-)	4.00±3.07 0.63-13.45	42	0.307	6.49±8.07 0.07-27.28	15	0.491
Relapse (+)	3.13±2.49 0.24-10.70	17		4.07±3.34 1.26-8.63	6	
Alive	3.82±3.17 0.63-13.45	38	0.914	5.70±7.89 0.07-27.28	13	0.926
Ex	3.65±2.51 0.24-10.70	20		5.81±6.29 1.26-18.64	7	
Lost to follow-up	2.68 2.68	1		8.63 8.63	1	

\*No statistical analysis was performed because there were fewer than six cases in the groups.